Literature DB >> 24952016

Liver-directed treatments for metastatic colorectal cancer.

Michael A Choti1.   

Abstract

OPINION STATEMENT: When possible, surgical resection remains the "gold standard" for the treatment of hepatic colorectal metastases. Liver resection should be considered when complete removal of all macroscopic disease can be achieved safely. For those patients with unresectable metastases, or when a patient may not be a candidate for liver resection, many choices are available to the clinician in an attempt to achieve locoregional control, including tumor ablation, intra-arterial therapies, and radiation therapy. Whereas with surgical resection, durable local control can be considered potentially curable, other liver-directed approaches currently are mostly palliative. Ongoing trials are being undertaken to evaluate the role of such cytoreductive therapies. During the initial evaluation of any patient who might be a candidate for liver-directed therapy, particularly when the intent may be curative, complete assessment with high-quality imaging should be done before any therapy to determine the full extent of disease. Most importantly, the establishment of a multidisciplinary team upon initial diagnosis can optimize the choice and sequencing of the various systemic and locoregional choices available to the colorectal cancer patient.

Entities:  

Mesh:

Year:  2014        PMID: 24952016     DOI: 10.1007/s11864-014-0297-1

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  58 in total

1.  Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial.

Authors:  P M Sanz-Altamira; L D Spence; M S Huberman; M R Posner; G Steele; L J Perry; K E Stuart
Journal:  Dis Colon Rectum       Date:  1997-07       Impact factor: 4.585

2.  Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.

Authors:  Chusilp Charnsangavej; Bryan Clary; Yuman Fong; Axel Grothey; Timothy M Pawlik; Michael A Choti
Journal:  Ann Surg Oncol       Date:  2006-09-01       Impact factor: 5.344

Review 3.  Microwave tumor ablation: mechanism of action, clinical results, and devices.

Authors:  Meghan G Lubner; Christopher L Brace; J Louis Hinshaw; Fred T Lee
Journal:  J Vasc Interv Radiol       Date:  2010-08       Impact factor: 3.464

4.  Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma.

Authors:  T Shibata; T Niinobu; N Ogata; M Takami
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

5.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

6.  Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience.

Authors:  Robert C G Martin; Charles R Scoggins; Kelly M McMasters
Journal:  Ann Surg Oncol       Date:  2009-08-26       Impact factor: 5.344

7.  Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.

Authors:  Georgios Karagkounis; Michael S Torbenson; Hubert D Daniel; Nilofer S Azad; Luis A Diaz; Ross C Donehower; Kenzo Hirose; Nita Ahuja; Timothy M Pawlik; Michael A Choti
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

8.  Percutaneous radiofrequency ablation of colorectal hepatic metastases - initial experience. An adjunct technique to systemic chemotherapy for those with inoperable colorectal hepatic metastases.

Authors:  T J White; S H Roy-Choudhury; D J Breen; J Cast; A Maraveyas; E F Smyth; J E Hartley; J R T Monson
Journal:  Dig Surg       Date:  2004-09-13       Impact factor: 2.588

9.  Radiofrequency ablation extends the scope of surgery in colorectal liver metastases.

Authors:  A Oshowo; A R Gillams; W R Lees; I Taylor
Journal:  Eur J Surg Oncol       Date:  2003-04       Impact factor: 4.424

10.  Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases.

Authors:  C J Zech; P Korpraphong; A Huppertz; T Denecke; M J Kim; W Tanomkiat; E Jonas; A Ba-Ssalamah
Journal:  Br J Surg       Date:  2014-03-20       Impact factor: 6.939

View more
  3 in total

1.  Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.

Authors:  Ciro Franzese; Tiziana Comito; Davide Franceschini; Mauro Loi; Elena Clerici; Pierina Navarria; Fiorenza De Rose; Lucia Di Brina; Pietro Mancosu; Giacomo Reggiori; Stefano Tomatis; Marta Scorsetti
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-13       Impact factor: 4.553

2.  β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases.

Authors:  Annalen Bleckmann; Lena-Christin Conradi; Kerstin Menck; Nadine Annette Schmick; Antonia Schubert; Eva Rietkötter; Jetcy Arackal; Peter Middel; Alexandra Schambony; Torsten Liersch; Kia Homayounfar; Tim Beißbarth; Florian Klemm; Claudia Binder; Tobias Pukrop
Journal:  Clin Exp Metastasis       Date:  2016-02-09       Impact factor: 5.150

3.  Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure.

Authors:  Marianna Di Scala; Irene Gil-Fariña; Cristina Olagüe; Africa Vales; Luciano Sobrevals; Puri Fortes; David Corbacho; Gloria González-Aseguinolaza
Journal:  Oncotarget       Date:  2016-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.